MindWalk Holdings (HYFT) Change in Account Payables (2023 - 2026)
MindWalk Holdings (HYFT) posted quarterly Change in Account Payables of $520137.8 for Q2 2026, down 19.02% year-over-year from $642294.0 in Q2 2025, and up 642.74% quarter-over-quarter from -$95835.8 in Q1 2026.
MindWalk Holdings (HYFT) Change in Account Payables (2023 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Change in Account Payables for 4 consecutive years, with $520137.8 the latest figure, recorded in Q2 2026.
- In Q2 2026, Change in Account Payables fell 19.02% year-over-year to $520137.8; the TTM figure through Apr 2026 stood at -$156327.3 (down 125.7% YoY), while the FY2026 annual figure was -$157573.3, down 126.54% from the prior year.
- Change in Account Payables climbed to $520137.8 in Q2 2026 per HYFT's latest filing, from -$95835.8 in the prior quarter.
- Across five years, Change in Account Payables topped out at $642294.0 in Q2 2025 and bottomed at -$779096.1 in Q1 2025.
- Historically, Change in Account Payables has averaged $3107.9 across 4 years, with a median of $159137.2 in 2025.
- On a YoY basis, Change in Account Payables climbed as much as 281.81% in 2025 and fell as far as 285.39% in 2025.
- MindWalk Holdings' Change in Account Payables stood at $322284.8 in 2023, then rose by 11.11% to $358089.2 in 2024, then plunged by 61.75% to $136967.0 in 2025, then surged by 279.75% to $520137.8 in 2026.
- Business Quant data shows HYFT's Change in Account Payables at $520137.8 in Q2 2026, -$95835.8 in Q1 2026, and $136967.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.03 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 520,137.79 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 7.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 520,137.79 |
| Apr 30, 2026 | 520,137.79 |
| Jan 31, 2026 | -95,835.77 |
| Jan 31, 2026 | -95,835.77 |
| Oct 31, 2025 | 136,967.01 |
| Oct 31, 2025 | 136,967.01 |
| Jul 31, 2025 | -717,596.34 |
| Jul 31, 2025 | -717,596.34 |
| Apr 30, 2025 | 642,294.02 |
| Apr 30, 2025 | 642,294.02 |
| Jan 31, 2025 | -779,096.10 |
| Jan 31, 2025 | -779,096.10 |
| Oct 31, 2024 | 358,089.18 |
| Oct 31, 2024 | 358,089.18 |
| Jul 31, 2024 | 387,065.35 |
| Jul 31, 2024 | 387,065.35 |
| Apr 30, 2024 | -353,272.21 |
| Apr 30, 2024 | -353,272.21 |
| Jan 31, 2024 | 579,201.92 |
| Jan 31, 2024 | 579,201.92 |